{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:32:15Z","timestamp":1772040735940,"version":"3.50.1"},"reference-count":22,"publisher":"American Academy of Pediatrics (AAP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:p>Preeclampsia is a hypertensive disorder of pregnancy that is a leading cause of maternal and perinatal morbidity and mortality. The condition presents heterogeneously at varying gestational ages. Primary prevention for preeclampsia with low-dose aspirin is recommended for patients with clinical risk factors. Despite extensive research, there is no clearly defined pathophysiology for preeclampsia or treatment for preeclampsia besides delivery of the placenta. Delivery of patients with preeclampsia without severe features is indicated in the early term period at 37 weeks\u2019 gestation and sooner if the patient develops severe preeclampsia. Management of preterm preeclampsia is guided by close assessment of the status of the pregnant woman and fetus, blood pressure control, and surveillance for any clinical progression to a more severe form of preeclampsia that may require preterm delivery. In a preterm gestation affected by preeclampsia, expectant management is intended to provide neonatal benefit though it does assume some maternal risk. Future research will hopefully further delineate the pathophysiology of the condition with the ultimate goal of finding a treatment to avoid associated morbidity and preterm delivery.<\/jats:p>","DOI":"10.1542\/neo.22-11-e760","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T09:35:13Z","timestamp":1635759313000},"page":"e760-e766","source":"Crossref","is-referenced-by-count":4,"title":["Hypertensive Disorders of Pregnancy"],"prefix":"10.1542","volume":"22","author":[{"given":"Daniela A.","family":"Febres-Cordero","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA"},{"name":"Department of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett C.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA"},{"name":"Department of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"issue":"6","key":"2021121010324188900_B1","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"16","key":"2021121010324188900_B2","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2017.3439","article-title":"Screening for preeclampsia: US Preventive Services Task Force Recommendation Statement","volume":"317","author":"US Preventive Services Task Force","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"2021121010324188900_B3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/AOG.0b013e3182324570","article-title":"Characterization of symptoms immediately preceding eclampsia","volume":"118","author":"Cooray","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2021121010324188900_B4","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/AOG.0000000000003020","article-title":"ACOG practice bulletin no. 203: chronic hypertension in pregnancy","volume":"133","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2014Obstetrics","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2021121010324188900_B5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-pathol-121808-102149","article-title":"Pathogenesis of preeclampsia","volume":"5","author":"Young","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"2021121010324188900_B6","doi-asserted-by":"crossref","first-page":"214365","DOI":"10.1155\/2011\/214365","article-title":"Maternal preeclampsia and neonatal outcomes","volume":"2011","author":"Backes","year":"2011","journal-title":"J Pregnancy"},{"issue":"1","key":"2021121010324188900_B7","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/AOG.0000000000002708","article-title":"ACOG committee opinion no. 743: low-dose aspirin use during pregnancy","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"8898","key":"2021121010324188900_B8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(94)92633-6","article-title":"CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women","volume":"343","author":"CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"2021121010324188900_B9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/uog.18816","article-title":"ASPRE trial: performance of screening for preterm pre-eclampsia. [published correction appears in Ultrasound Obstet Gynecol. 2017 Dec;50(6):807]","volume":"50","author":"Rolnik","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2021121010324188900_B10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.placenta.2019.07.003","article-title":"Are maternal and neonatal outcomes different in placental abruption between women with and without preeclampsia?","volume":"85","author":"Han","year":"2019","journal-title":"Placenta"},{"issue":"4","key":"2021121010324188900_B11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.clp.2004.06.008","article-title":"Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome","volume":"31","author":"Barton","year":"2004","journal-title":"Clin Perinatol"},{"issue":"4","key":"2021121010324188900_B12","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/0002-9378(93)90043-I","article-title":"Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome)","volume":"169","author":"Sibai","year":"1993","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2021121010324188900_B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/sper.2002.29838","article-title":"Maternal medical disease: risk of antepartum fetal death","volume":"26","author":"Simpson","year":"2002","journal-title":"Semin Perinatol"},{"issue":"6","key":"2021121010324188900_B14","doi-asserted-by":"crossref","first-page":"544.e1","DOI":"10.1016\/j.ajog.2013.08.019","article-title":"Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease","volume":"209","author":"Lisonkova","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2021121010324188900_B15","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/0002-9378(94)90104-X","article-title":"Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks\u2019 gestation: a randomized controlled trial","volume":"171","author":"Sibai","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2021121010324188900_B16","first-page":"1070","article-title":"Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks\u2019 gestation: a randomized controlled trial","volume":"76","author":"Odendaal","year":"1990","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2021121010324188900_B17","doi-asserted-by":"crossref","first-page":"425.e1","DOI":"10.1016\/j.ajog.2013.08.016","article-title":"Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial","volume":"209","author":"Vigil-De Gracia","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"2021121010324188900_B18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.preghy.2020.03.006","article-title":"Adverse maternal and neonatal outcomes among women with preeclampsia with severe features &lt;34 weeks gestation with versus without comorbidity","volume":"20","author":"Venkatesh","year":"2020","journal-title":"Pregnancy Hypertens"},{"issue":"1","key":"2021121010324188900_B19","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1055\/s-0035-1565923","article-title":"Neonatal thrombocytopenia as a consequence of maternal preeclampsia","volume":"6","author":"Kalagiri","year":"2016","journal-title":"AJP Rep"},{"issue":"2","key":"2021121010324188900_B20","first-page":"e29","article-title":"Medically indicated late-preterm and early-term deliveries: ACOG committee opinion, number 818","volume":"137","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Obstetric Practice, Society for Maternal-Fetal Medicine","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"9694","key":"2021121010324188900_B21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0140-6736(09)60736-4","article-title":"Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks\u2019 gestation (HYPITAT): a multicentre, open-label randomised controlled trial","volume":"374","author":"Koopmans","year":"2009","journal-title":"Lancet"},{"issue":"9321","key":"2021121010324188900_B22","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(02)08778-0","article-title":"Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial","volume":"359","author":"Altman","year":"2002","journal-title":"Lancet"}],"container-title":["NeoReviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/22\/11\/e760\/1192628\/neoreviews_072021rev00117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/22\/11\/e760\/1192628\/neoreviews_072021rev00117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T23:10:51Z","timestamp":1639177851000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/neoreviews\/article\/22\/11\/e760\/181265\/Hypertensive-Disorders-of-Pregnancy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/neo.22-11-e760","relation":{},"ISSN":["1526-9906"],"issn-type":[{"value":"1526-9906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}